Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience

研究成果: Article同行評審

8 引文 斯高帕斯(Scopus)

指紋

深入研究「Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience」主題。共同形成了獨特的指紋。

Medicine & Life Sciences